Dr. Ravi Vij | CureTalks
Dr. Vij is a Professor of Medicine at Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. He serves on numerous committees including the Core Transplant Committee of the CALGB, Project Review Committee of the Multiple Myeloma Research Consortium and on the Guidelines Committee for the National Comprehensive Cancer Network (NCCN). He is involved in several collaborations with other members of the Siteman Cancer Center in studying the biology of plasma cell dyscrasias. He has authored publications and served as a reviewer for prestigious journals. Dr Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. His research focuses on multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij completed his medical degree at Maulana Azad Medical College, Residency at Rush University Medical Center, and Fellowship at Washington University.
Related Talks
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose…
Allogenic Transplants with Myeloma Expert Dr. Vij & MMRF
Dr. Ravi Vij of Washington University School of Medicine discusses the pros and cons of Allogenic Transplants and Anne Quinn Young of MMRF…
Latest developments in multiple myeloma with Dr. Ravi Vij
In the first episode of the Multiple Myeloma Curetalk with Dr. Ravi Vij of Washington University, St. Louis, we discuss the latest developments…